Several non-selective HDAC inhibitors have already been approved by the U.S. Food and Drug Administration (FDA) for cancer treatment including vorinostat, romidepsin, and panobinostat, but they show toxicity to normal tissues during cancer therapy. The gene discussed is HDAC9; the disease is cancer.